Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.03. | Inhibitor Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
14.12.23 | Inhibitor Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.11.23 | Inhibitor Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BEAM THERAPEUTICS | 23,900 | -1,69 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
QIAGEN | 37,470 | +1,19 % | Qiagen: Aufschwung in der zweiten Jahreshälfte | Analysten der Deutschen Bank erwarten beim Jahresauftakt von Qiagen keine Überraschungen. Das Unternehmen prognostiziert einen Umsatz von rund 455 Millionen Dollar, das wäre ein Minus von rund 6 Prozent.... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 9,100 | -3,70 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,350 | -0,68 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
EVOTEC | 13,260 | -1,41 % | Aixtron, Deutsche Bank, Evotec, RWE, Valneva, Varta - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
ADMA BIOLOGICS | 6,270 | +1,13 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen | |
APOGEE THERAPEUTICS | 46,910 | -2,98 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
IMMUNOME | 15,480 | -9,90 % | Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 25,980 | -1,29 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
ARCELLX | 51,64 | -5,25 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 40,095 | -5,59 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 | ||
VERA THERAPEUTICS | 38,010 | -3,72 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
NUVALENT | 62,76 | -0,48 % | Jefferies starts Nuvalent at buy, cites lung cancer drug candidates | ||
MORPHOSYS | 67,70 | 0,00 % | Formycon, Defence Therapeutics, Morphosys - Mächtig Bewegung in der Biotechbranche | Aktuell richtet sich der Fokus der Anleger neben den wichtigsten Indizes wie DAX oder Dow Jones vor allem auf Gold oder Bitcoin, dagegen ist vom Biotechnologiesektor in den hiesigen Gazetten wenig zu... ► Artikel lesen | |
CULLINAN ONCOLOGY | 15,650 | -13,34 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases | CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep... ► Artikel lesen |